Pharmacyclics LLC, an AbbVie Company
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$746.2M
Doctors Paid
12,761
Transactions
98,683
2023 Total
$178.5M
Payment Breakdown by Category
Research$736.2M (98.7%)
Consulting$1.5M (0.2%)
Food & Beverage$1.4M (0.2%)
Travel$1.2M (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $736.2M | 28,332 | 98.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.2M | 1,820 | 0.6% |
| Consulting Fee | $1.5M | 715 | 0.2% |
| Food and Beverage | $1.4M | 61,360 | 0.2% |
| Travel and Lodging | $1.2M | 4,363 | 0.2% |
| Grant | $978,444 | 71 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $570,362 | 171 | 0.1% |
| Education | $158,777 | 1,851 | 0.0% |
Payments by Type
Research
$736.2M
28,332 transactions
General
$10.0M
70,351 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| EA9161: A Randomized Phase III Study of a Targeted Therapy Combination versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) | $146.8M | 0 | 33 |
| A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients ( ? 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) | $46.0M | 0 | 19 |
| Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | $45.3M | 0 | 17 |
| A Randomized Phase III Study of a Targeted Therapy Combination versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) | $43.6M | 0 | 16 |
| E1912: A Randomized Phase III Study of PCI-32765 based-therapy versus standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) | $38.8M | 0 | 16 |
| E1912: A Randomized Phase III Study of PCI-32765 based-therapy versus standard Fludarabine- Cyclophosphamide- and Rituximab (FCR) chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) | $35.4M | 0 | 17 |
| Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | $35.1M | 0 | 16 |
| A Randomized Phase III Study of PCI-32765 based-therapy versus standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) | $33.4M | 0 | 18 |
| A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) | $31.9M | 0 | 15 |
| A041202: A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (? 65 years of age) with Chronic Lymphocytic Leukemia (CLL) | $26.2M | 0 | 16 |
| A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (65 years of age) with Chronic Lymphocytic Leukemia (CLL) | $24.2M | 0 | 15 |
| Randomized study of ibrutinib versus ibrutinib plus rituximab (i versus iR) in patients with relapsed chronic lymphocytic leukemia (CLL) | $20.2M | 0 | 17 |
| A Phase II Study of Ibrutinib Plus Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients with Newly Diagnosed MCL | $10.4M | 0 | 12 |
| A Phase II Study of Ibrutinib in combination with Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients with CLL | $10.0M | 0 | 27 |
| Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma with High-Risk Smoldering Disease | $9.1M | 0 | 16 |
| Phase II, single arm, open label single-center study of Obinutuzumab and Ibrutinib in the front line treatment of Indolent Non-Hodgkins Lymphomas | $8.9M | 0 | 22 |
| PCYC-1142-CA | $7.3M | 19 | 796 |
| Phase II study on the combination of Ibrutinib and venetoclax in treatment na?ve patients with Waldenstr?m Macroglobulinemia | $7.1M | 0 | 21 |
| A Pilot Phase II Study of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | $6.0M | 0 | 3 |
| A Phase II Study of the Brutons Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed and Refractory Patients with Chronic Lymphocytic Lymphoma (CLL)/Small Lymphocytic Leukemia (SLL) and B-cell Prolymphocytic Leukemia (B-PLL) | $5.5M | 0 | 9 |
| A phase II study of Ibrutinib for patients with chronic lymphocyctic leukemia (CLL) or small lymphocyctic lymphoma (SLL) who need therapy and are older than 65 or have a 17p deletion | $5.5M | 0 | 4 |
| A phase II study of ibrutinib for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need therapy and are older than 65 or have a 17p deletion | $4.9M | 0 | 3 |
| A Multicenter Phase 2 Study of the Brutons Tyrosine Kinase Inhibitor PCI-32765 for Treatment of Relapsed Hairy Cell Leukemia | $4.0M | 0 | 12 |
| PCYC-1141-CA | $4.0M | 12 | 1,604 |
| A Phase II Trial of the Combination of Obinutuzumab, Ibrutinib and Venetoclax in patients with previously untreated follicular Lymphoma | $3.9M | 0 | 25 |
| CTEP 9268: A Multicenter Phase 2 Study of the Brutons Tyrosine Kinase Inhibitor PCI-32765 for Treatment of Relapsed Hairy Cell Leukemia | $3.7M | 0 | 14 |
| A Pilot Phase II Study of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocyctic Leukemia/Small Lymphocyctic Lymphoma (CLL/SLL) | $3.7M | 0 | 2 |
| CTEP 9268: A Multicenter Phase 2 Study of the Bruton?s Tyrosine Kinase Inhibitor PCI-32765 for Treatment of Relapsed Hairy Cell Leukemia | $3.5M | 0 | 10 |
| PCYC-1143-CA | $3.2M | 11 | 1,678 |
| Minimal residual disease Eradication with Ibrutinib Therapy (MERIT) in patients with chronic lymphocytic leukemia after frontline therapy | $3.2M | 0 | 7 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Asad Dean, Md, MD | Medical Oncology | Fort Worth, TX | $482,428 | $0 |
| Dr. Nakhle Saba, Md, MD | Specialist | Baton Rouge, LA | $333,521 | $0 |
| Ryan Jacobs, Md, MD | Internal Medicine | Charlotte, NC | $269,834 | $0 |
| Dr. Eric Jacobsen, Md, MD | Hematology & Oncology | Boston, MA | $238,255 | $0 |
| Jacalyn Rosenblatt, M.d, M.D | Hematology | Boston, MA | $230,680 | $0 |
| Mr. Ruemu Birhiray, Md, MD | Hematology & Oncology | Indianapolis, IN | $227,588 | $0 |
| Perry Cook, M.d, M.D | Hematology & Oncology | Brooklyn, NY | $212,769 | $0 |
| Dr. Joseph Mikhael, M.d, M.D | Hematology | Scottsdale, AZ | $200,989 | $0 |
| Cyrus Khan, M.d, M.D | Hematology & Oncology | Pittsburgh, PA | $198,973 | $0 |
| Anthony Letai, Md, MD | Hematology & Oncology | Boston, MA | $198,950 | $0 |
| John Pagel, Md Phd, MD PHD | Hematology & Oncology | Seattle, WA | $176,435 | $0 |
| Imad Tabbara, M.d, M.D | Hematology & Oncology | Washington, DC | $148,538 | $0 |
| Dr. Bipinkumar Amin, Md, MD | Hematology & Oncology | Watertown, SD | $145,032 | $0 |
| Javier Pinilla-Ibarz, Md, MD | Internal Medicine | Tampa, FL | $140,804 | $0 |
| Ilan Shapira, Md, MD | Internal Medicine | New York, NY | $139,793 | $0 |
| Dr. Daniel Landau, Md, MD | Hematology & Oncology | Orlando, FL | $136,574 | $0 |
| Jeffrey Zwicker, M.d, M.D | Hematology & Oncology | New York, NY | $125,220 | $0 |
| Steven Schuster, M.d, M.D | Internal Medicine | Fort Collins, CO | $124,469 | $0 |
| Dr. Morton Coleman, Md, MD | Hematology & Oncology | New York, NY | $115,683 | $0 |
| Michael Schuster, Md, MD | Internal Medicine | New York, NY | $111,329 | $0 |
| Darren Brennan, M.d, M.D | Diagnostic Radiology | Marlborough, MA | $85,835 | $0 |
| Joseph Moore, M.d, M.D | Internal Medicine | Durham, NC | $82,874 | $0 |
| Dr. Sujith Kalmadi, Md, MD | Hematology & Oncology | Chandler, AZ | $77,027 | $0 |
| Dr. Wb Younger, Md, MD | Hematology & Oncology | Boston, MA | $76,395 | $0 |
| Kathleen Dietz-Lovett, Np, NP | Adult Health | Hyannis, MA | $74,120 | $0 |
About Pharmacyclics LLC, an AbbVie Company
Pharmacyclics LLC, an AbbVie Company has made $746.2M in payments to 12,761 healthcare providers, recorded across 98,683 transactions in the CMS Open Payments database. In 2023, the company paid $178.5M. The top product by payment volume is IMBRUVICA ($686.3M).
Payments were distributed across 142 medical specialties. The top specialty by payment amount is Hematology & Oncology ($4.3M to 3,705 doctors).
Payment categories include: Food & Beverage ($1.4M), Consulting ($1.5M), Research ($736.2M), Travel & Lodging ($1.2M).
Pharmacyclics LLC, an AbbVie Company is associated with 3 products in the CMS Open Payments database.